BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 31474546)

  • 1. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial.
    Lee JW; Lee SE; Jung CW; Park S; Keta H; Park SK; Kim JA; Oh IH; Jang JH
    Lancet Haematol; 2019 Nov; 6(11):e562-e572. PubMed ID: 31474546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study.
    Jang JH; Tomiyama Y; Miyazaki K; Nagafuji K; Usuki K; Uoshima N; Fujisaki T; Kosugi H; Matsumura I; Sasaki K; Kizaki M; Sawa M; Hidaka M; Kobayashi N; Ichikawa S; Yonemura Y; Enokitani K; Matsuda A; Ozawa K; Mitani K; Lee JW; Nakao S
    Br J Haematol; 2021 Jan; 192(1):190-199. PubMed ID: 33152120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
    Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
    Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
    Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
    Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
    Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
    Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
    Kantarjian H; Fenaux P; Sekeres MA; Becker PS; Boruchov A; Bowen D; Hellstrom-Lindberg E; Larson RA; Lyons RM; Muus P; Shammo J; Siegel R; Hu K; Franklin J; Berger DP
    J Clin Oncol; 2010 Jan; 28(3):437-44. PubMed ID: 20008626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
    Janssens A; Rodeghiero F; Anderson D; Chong BH; Boda Z; Pabinger I; Červinek L; Terrell DR; Wang X; Franklin J
    Ann Hematol; 2016 Jun; 95(7):1077-87. PubMed ID: 27130310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
    Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Iwato K; Okamoto S; Kurokawa M; Kirito K; Hashino S; Ninomiya H; Mori S; Yonemura Y; Usuki K; Wei H; Lizambri R
    Int J Hematol; 2012 Jun; 95(6):652-9. PubMed ID: 22532046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.
    Kuter DJ; Bussel JB; Newland A; Baker RI; Lyons RM; Wasser J; Viallard JF; Macik G; Rummel M; Nie K; Jun S
    Br J Haematol; 2013 May; 161(3):411-23. PubMed ID: 23432528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.
    Grainger J; Bussel J; Tarantino M; Cooper N; Beam D; Despotovic J; Maschan A; Wang K; Eisen M; Bowers C
    Blood Adv; 2023 Feb; 7(3):396-405. PubMed ID: 35413092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
    Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Okamoto S; Kurokawa M; Kirito K; Yonemura Y; Mori S; Usuki K; Iwato K; Hashino S; Wei H; Lizambri R
    Int J Hematol; 2011 Jul; 94(1):71-80. PubMed ID: 21706145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
    Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study.
    Elalfy MS; Abdelmaksoud AA; Eltonbary KY
    Ann Hematol; 2011 Nov; 90(11):1341-4. PubMed ID: 21318572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
    Steurer M; Quittet P; Papadaki HA; Selleslag D; Viallard JF; Kaiafa G; Janssens A; Kozak T; Wadenvik H; Schoonen M; Belton L; Kreuzbauer G
    Eur J Haematol; 2017 Feb; 98(2):112-120. PubMed ID: 27557853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.